Diffusion-weighted Imaging of the Liver with Multiple b Values: Effect of Diffusion Gradient Polarity and Breathing Acquisition on Image Quality and Intravoxel …
…, M Orton, A de Oliveira, T Feiweier, ML Vachon… - Radiology, 2013 - pubs.rsna.org
Purpose To optimize intravoxel incoherent motion (IVIM) diffusion-weighted (DW) imaging
by estimating the effects of diffusion gradient polarity and breathing acquisition scheme on …
by estimating the effects of diffusion gradient polarity and breathing acquisition scheme on …
Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons
…, G De Serres, M Tremblay, ML Vachon… - The Journal of …, 2006 - academic.oup.com
Sequencing studies of the glycoprotein G gene were performed in human respiratory syncytial
virus (hRSV) strains detected by reverse-transcription polymerase chain reaction directly …
virus (hRSV) strains detected by reverse-transcription polymerase chain reaction directly …
Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV
…, B Conway, N Pick, ML Vachon… - Clinical Infectious …, 2017 - academic.oup.com
Background. Highly effective hepatitis C virus (HCV) therapies have spurred a scale-up of
treatment to populations at greater risk of reinfection after sustained virologic response (SVR). …
treatment to populations at greater risk of reinfection after sustained virologic response (SVR). …
How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV/HCV in the real world?
…, R Sandre, JM Tyndall, ML Vachon… - Clinical Infectious …, 2016 - academic.oup.com
Background. Direct-acting antivirals (DAAs) against hepatitis C virus (HCV) have been
described as revolutionary. However, it remains uncertain how effective these drugs will be for …
described as revolutionary. However, it remains uncertain how effective these drugs will be for …
Eliminating structural barriers: the impact of unrestricted access on hepatitis C treatment uptake among people living with human immunodeficiency virus
…, J Gill, A Wong, ML Vachon… - Clinical Infectious …, 2020 - academic.oup.com
Background High costs of direct-acting antivirals (DAAs) have led health-care insurers to
limit access worldwide. Using a natural experiment, we evaluated the impact of removing …
limit access worldwide. Using a natural experiment, we evaluated the impact of removing …
Mortality in hepatitis C virus–infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy
AD Branch, ML Van Natta, ML Vachon… - Clinical infectious …, 2012 - academic.oup.com
Background. Before the introduction of combination antiretroviral therapy (cART), patients
infected with the human immunodeficiency virus (HIV) rarely died of liver disease. In resource-…
infected with the human immunodeficiency virus (HIV) rarely died of liver disease. In resource-…
[HTML][HTML] Human parainfluenza type 4 infections, Canada
ML Vachon, N Dionne, E Leblanc… - Emerging infectious …, 2006 - ncbi.nlm.nih.gov
During the fall/winter season of 2004–05, we found 9 respiratory specimens positive for human
parainfluenza virus type 4 (HPIV-4) in our laboratory (43% of all HPIVs) from patients with …
parainfluenza virus type 4 (HPIV-4) in our laboratory (43% of all HPIVs) from patients with …
Ledipasvir-sofosbuvir plus ribavirin in treatment-naive patients with hepatitis C virus genotype 3 infection: an open-label study
…, P Marotta, E Huchet, ML Vachon… - Clinical Infectious …, 2017 - academic.oup.com
Background Patients chronically infected with genotype 3 hepatitis C virus (HCV) have faster
disease progression and are less responsive to current direct-acting antiviral regimens …
disease progression and are less responsive to current direct-acting antiviral regimens …
Real‐world impact of direct acting antiviral therapy on health‐related quality of life in HIV/Hepatitis C co‐infected individuals
Clinical trial results of direct acting antivirals ( DAA s) for the treatment of hepatitis C virus (
HCV ) have shown improvements in health‐related quality of life (HR‐QoL). However, the …
HCV ) have shown improvements in health‐related quality of life (HR‐QoL). However, the …
The era of direct-acting antivirals has begun: the beginning of the end for HCV?
ML Vachon, DT Dieterich - Seminars in liver disease, 2011 - thieme-connect.com
The year 2011 marks the dawn of the new era of direct-acting antivirals for hepatitis C. For
the first time since 1998, the US Food and Drug Administration approved two new antiviral …
the first time since 1998, the US Food and Drug Administration approved two new antiviral …